Evommune, Inc. (NYSE:EVMN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Evommune, Inc. (NYSE:EVMN) have been assigned a consensus rating of “Moderate Buy” from the fourteen analysts that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $45.6250.

EVMN has been the subject of a number of recent research reports. Oppenheimer began coverage on Evommune in a report on Tuesday, April 7th. They set an “outperform” rating and a $50.00 price objective for the company. William Blair cut Evommune from an “outperform” rating to a “market perform” rating in a research report on Monday, June 29th. Stifel Nicolaus initiated coverage on Evommune in a report on Friday, May 1st. They set a “buy” rating and a $54.00 price target for the company. Morgan Stanley lowered their price target on Evommune from $55.00 to $26.00 and set an “overweight” rating for the company in a research report on Tuesday, June 30th. Finally, Raymond James Financial cut Evommune from a “strong-buy” rating to a “moderate buy” rating in a research note on Monday, June 29th.

Insider Buying and Selling

In related news, insider Jeegar Pravinkumar Patel sold 1,488 shares of the business’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $22.50, for a total transaction of $33,480.00. Following the transaction, the insider directly owned 46,403 shares in the company, valued at approximately $1,044,067.50. The trade was a 3.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Luis C. Pena sold 7,438 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $22.71, for a total value of $168,916.98. Following the completion of the transaction, the chief executive officer owned 630,458 shares in the company, valued at $14,317,701.18. The trade was a 1.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 100,854 shares of company stock valued at $2,279,142 over the last 90 days.

Institutional Investors Weigh In On Evommune

Several large investors have recently made changes to their positions in EVMN. China Universal Asset Management Co. Ltd. purchased a new stake in Evommune during the fourth quarter worth about $34,000. Strs Ohio bought a new position in Evommune during the first quarter valued at $41,000. The Manufacturers Life Insurance Company purchased a new stake in Evommune in the fourth quarter worth $179,000. XTX Topco Ltd bought a new stake in shares of Evommune in the fourth quarter valued at $321,000. Finally, Oxford Asset Management LLP bought a new stake in shares of Evommune in the fourth quarter valued at $335,000.

Evommune Stock Performance

Shares of Evommune stock opened at $12.16 on Tuesday. The stock has a market capitalization of $438.00 million and a PE ratio of -1.28. Evommune has a 52 week low of $11.50 and a 52 week high of $33.20. The stock has a 50 day moving average price of $19.24 and a two-hundred day moving average price of $21.82.

Evommune (NYSE:EVMN) last posted its earnings results on Thursday, May 7th. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.19. Research analysts forecast that Evommune will post -2.83 EPS for the current year.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.